Request for materials

Tapping into Japan’s Opportunity in Regenerative Medicine and Cell & Gene Therapy

The cell and gene therapy and regenerative medicine (CGT&RM) market in Japan is set to grow to a staggering $6.3 billion by 2030. An aging population coupled with a progressive regulatory environment, makes this an untapped gateway to the world.

While Japan offers a wealth of innovative and industry-leading legislation to help streamline the progression of CGT&RM development, choosing the right CDMO with which to partner is key.

Download our eBook to learn more about:

Japan’s booming CGT&RM market
The growing demand for novel therapies
Japan’s success-enabling regulatory landscape for CGT&RM development
How Japan-based Contract Development and Manufacturing Organizations (CDMOs) can help fast-track you to CGT&RM success

Fill out this brief form to download your copy:

First Name*
Last Name*
E-mail*	We cannot receive requests through free e-mail address (e.g., @gmail.com).
Company Name*
Department
Job Title*

Handling of Personal Information

We collect your personal information for the purposes of sending materials, providing replies to inquiries, or including you in marketing activities. All data is managed appropriately. Personal information will not be disclosed or provided to a third party without consent from the customer (except where disclosure is required by law or regulations, etc.).

Please refer to our Privacy Policy with respect to treatment of the customers' personal information.

I agree*